Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field., part of Takeda. FDA records under its name, each linked to the record. See the Takeda group view.
As of Nov 16, 2026, FDA's public records list Takeda Development Center Americas with 2 drug recalls. The most recent is a drug recall dated Nov 6, 2018: AMITIZA (lubiprostone) capsules 8 mcg. 60-count bottle, Rx Only. Marketed by: Sucampo Ph….
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
A hatched bar is a year that is not over, so its count covers only part of the year.
| Nov 6, 2018 | AMITIZA (lubiprostone) capsules 8 mcg. 60-count bottle, Rx Only. Marketed by: Sucampo Pharma Americas, LLC, Rockville MD 20850 and Takeda PhClass III · Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testin | Drug recalls |
| Sep 10, 2018 | Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 15 mg/1000 mg, Rx Only, 30 tablet bottle, Distributed by: TakedaClass II · Defective Delivery System: tablets may be missing, in whole or in part, the laser drilled holes on the metformin core of | Drug recalls |
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata. How this page is built